



COPY OF PAPER
ORIGINALLY FILED

6C T.O Receipt

PATENT

Attorney Docket No. 28967/34891A

IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE

Applicants: Alitalo et al.

Serial No.: 09/765,534

Filed: January 19, 2001

For: Flt4 (VEGFR-3) as a Target
for Tumor Imaging and Anti-
Tumor Therapy

Examiner: TBD

Group Art Unit: 1644

I hereby certify that this paper is being
deposited with the United States Postal
Service as first class mail, postage
prepaid, in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, DC 20231 on this date:

May 9, 2002

Eric M. Brusca

REQUEST TO CORRECT FILING RECEIPT

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

Sir:

Attached hereto are copies of a filing receipt issued by the Patent Office and page 1 of the patent application as filed. It will be apparent from the patent application that the filing receipt contains an incomplete priority claim. The applicants respectfully request issuance of a new filing receipt that identifies all of the priority applications, dating back to 1992. Because the application claims priority back to 1992, it is entitled to special status for examination purposes.

Respectfully submitted,

MARSHALL, GERSTEIN, & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

By:

David A. Gass
Registration No. 38,153



- 1 -

Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY

This application is a continuing application which claims priority from United States Patent Application Serial No. 09/169,079 filed October 9, 1998; and
5 from United States Patent Application Serial No. 08/901,710, filed July 28, 1997, now U.S. Patent No. 6,107,046; and from U.S. Patent Application Serial No. 08/340,011, filed November 14, 1994, now U.S. Patent No. 5,776,755; and from United States Patent Application Serial No. 08/257,754, filed June 9, 1994, now abandoned; the
10 latter two of which in turn are continuations-in-part of United States Patent Application Serial No. 07/959,951, filed on October 9, 1992, now abandoned. All of these applications are incorporated herein by reference, in their entireties.

Field of the Invention

The present invention relates generally to genes for receptors, specifically genes for receptor tyrosine kinases, their insertion into recombinant DNA
15 vectors, and the production of the resulting proteins in host strains of microorganisms and host eukaryotic cells. More specifically, the present invention is directed to Flt4, a receptor tyrosine kinase; to nucleotide sequences encoding Flt4; to methods for the generation of DNAs encoding Flt4 and their gene products; to nucleic acid probes which specifically recognize (hybridize to) nucleic acids encoding such receptors; to
20 antibodies that specifically recognize such receptors; and to methods of using such probes and antibodies and other Flt4 binding compounds, e.g., for identifying lymphatic vessels and high endothelial venules (HEV) in animal and human tissues and augmenting or preventing the growth of Flt4-expressing cells in pathological conditions.

25

BACKGROUND

The cellular behavior responsible for the development, maintenance and repair of differentiated cells and tissues is regulated, in large part, by intercellular signals conveyed via growth factors and similar ligands and their receptors. The



UNITED STATES PATENT AND TRADEMARK OFFICE

COPY OF PAPER
ORIGINALLY FILED
 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/765,534	01/19/2001	1644	355	28967/34891A	13	19	2

04743

 MARSHALL, O'TOOLE, GERSTEIN, MURRAY & BORUN
 6300 SEARS TOWER
 233 SOUTH WACKER DRIVE
 CHICAGO, IL 60606-6402

CONFIRMATION NO. 1420

FILING RECEIPT



OC000000007318664

Date Mailed: 01/16/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

 Kari Alitalo, Espoo, FINLAND;
 Olga Aprelikova, North Potomac, MD;
 Katri Pajusola, Helsinki, FINLAND;
 Elina Armstrong, Philadelphia, PA;
 Jaana Korhonen, Montreal, CANADA;
 Arja Kaipainen, Boston, MA;

RECEIVED

JAN 24 2002

MARSHALL GERSTEIN

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CONTINUATION OF 09/169,079 10/09/1998

RECEIVED

JAN 24 2002

MARSHALL

Foreign Applications

If Required, Foreign Filing License Granted 01/16/2002

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).